5-Benzimidazolecarboxylic acidCAS# 15788-16-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 15788-16-6 | SDF | Download SDF |
| PubChem ID | 459456 | Appearance | Powder |
| Formula | C8H6N2O2 | M.Wt | 162 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 3H-benzimidazole-5-carboxylic acid | ||
| SMILES | C1=CC2=C(C=C1C(=O)O)NC=N2 | ||
| Standard InChIKey | COYPLDIXZODDDL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C8H6N2O2/c11-8(12)5-1-2-6-7(3-5)10-4-9-6/h1-4H,(H,9,10)(H,11,12) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
5-Benzimidazolecarboxylic acid Dilution Calculator
5-Benzimidazolecarboxylic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.1728 mL | 30.8642 mL | 61.7284 mL | 123.4568 mL | 154.321 mL |
| 5 mM | 1.2346 mL | 6.1728 mL | 12.3457 mL | 24.6914 mL | 30.8642 mL |
| 10 mM | 0.6173 mL | 3.0864 mL | 6.1728 mL | 12.3457 mL | 15.4321 mL |
| 50 mM | 0.1235 mL | 0.6173 mL | 1.2346 mL | 2.4691 mL | 3.0864 mL |
| 100 mM | 0.0617 mL | 0.3086 mL | 0.6173 mL | 1.2346 mL | 1.5432 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 5-Nonyloxytryptamine oxalate
Catalog No.:BCC6839
CAS No.:157798-13-5
- Gypenoside A
Catalog No.:BCN8459
CAS No.:157752-01-7
- Gentiournoside D
Catalog No.:BCN7855
CAS No.:157722-21-9
- Perifosine
Catalog No.:BCC3673
CAS No.:157716-52-4
- 7-Xylosyl-10-deacetylbaccatin III
Catalog No.:BCN7668
CAS No.:157664-03-4
- Prenylpiperitol
Catalog No.:BCN1706
CAS No.:157659-20-6
- NSC 632839 hydrochloride
Catalog No.:BCC2088
CAS No.:157654-67-6
- Boc-Pro-OH
Catalog No.:BCC3435
CAS No.:15761-39-4
- Boc-Ala-OH
Catalog No.:BCC3047
CAS No.:15761-38-3
- (S)-SNAP 5114
Catalog No.:BCC7117
CAS No.:157604-55-2
- BTS
Catalog No.:BCC5425
CAS No.:1576-37-0
- Coronarin D methyl ether
Catalog No.:BCN1705
CAS No.:157528-81-9
- (Z)-2-decenoic acid
Catalog No.:BCC1295
CAS No.:15790-91-7
- Chitinase-IN-1
Catalog No.:BCC5533
CAS No.:1579991-61-9
- Chitinase-IN-2
Catalog No.:BCC5534
CAS No.:1579991-63-1
- ortho-iodoHoechst 33258
Catalog No.:BCC1824
CAS No.:158013-41-3
- meta-iodoHoechst 33258
Catalog No.:BCC1739
CAS No.:158013-42-4
- para-iodoHoechst 33258
Catalog No.:BCC1838
CAS No.:158013-43-5
- 5-Hydroxy-6,7,8-trimethoxycoumarin
Catalog No.:BCN7470
CAS No.:1581248-32-9
- 21-O-Tigloylgymnemagenin
Catalog No.:BCN7854
CAS No.:1581276-63-2
- Fmoc-Ser(HPO3Bzl)-OH
Catalog No.:BCC3543
CAS No.:158171-14-3
- Naringenin-7-O-glucuronide
Catalog No.:BCC8215
CAS No.:158196-34-0
- Methyl 3-(4-methoxyphenyl)propanoate
Catalog No.:BCN4051
CAS No.:15823-04-8
- Pyraclonil
Catalog No.:BCC8073
CAS No.:158353-15-2
Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid.[Pubmed:12445730]
J Immunol Methods. 2002 Dec 20;271(1-2):65-75.
Drug-specific monoclonal antibodies (MAbs) were produced against the very small drug hapten (162.15 Da), 5-Benzimidazolecarboxylic acid, an analogue of 2-(4-Thiazolyl)benzimidazole (TBZ) but lacking the thiol group. TBZ is widely used as a broad-spectrum anthelmintic in various animal species and humans and also as a food preservative and agricultural fungicide. The anti-5-Benzimidazolecarboxylic acid antibodies produced have potential use for extraction and/or detection of protein-bound residue forms of TBZ. Three in vivo immunisation regimes (with combinations of two related small drug haptens and two different adjuvants/carrier molecules) and an in vitro immunisation procedure using a combination of three related unconjugated small drug haptens were investigated. Specificity for the hapten immunogen/s was initially determined using two different ELISA procedures. BIACORE analysis, in conjunction with drug binding inhibition studies, was used to confirm the specificity of a small number of selected clones. In vivo immunisation with a drug molecule conjugated to a lipopeptide/T-cell epitope, which acts both as a carrier molecule and an adjuvant was the most useful of the methods tested for the production of specific MAbs to a typically very small hapten with low immunogenic properties.
